



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin receives FDA approval for its Oral Contraceptive Pirmella™ 7/7/7 and Pirmella™ 1/35 Tablets
Generic of Ortho Novum 7/7/7® and Generic of Ortho Novum 1/35® Oral Contraceptive Tablets

Mumbai, Baltimore, April 26, 2013: Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively Lupin) has received final approval for its Pirmella™ 7/7/7 (Norethindrone and Ethinyl Estradiol Tablets USP, 0.5 mg/0.035 mg, 0.75 mg/0.035 mg and 1mg/0.035 mg) and Pirmella™ 1/35 Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 1 mg/0.035 mg) from the United States Food and Drugs Administration (US FDA) to market a generic version of Janssen Pharmaceuticals, Inc.'s Ortho-Novum® 7/7/7 Tablets and Ortho-Novum® 1/35 tablets. Lupin would commence shipping the product shortly.

Lupin's Pirmella™ 7/7/7 and Pirmella™ 1/35 Tablets is indicated for the prevention of pregnancy in women who elect to use the product as a method of contraception.

The total sales for both Ortho Novum 7/7/7® and Ortho Novum 1/35® Oral Contraceptive Tablets stood at **USD 96.5 million (IMS MAT Dec 2012)**.

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2012, Lupin's Consolidated Total Income and Profit after Tax were Rs. 70,972 million (USD 1.49 billion) and Rs.8,676 million (USD 182 million) respectively. Please visit <http://www.lupinworld.com> for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>

For further information or queries please contact -

Shamsher Gorawara

Head – Corporate Communications

Lupin Limited

Ph: +91 98 20 338 555

Email: shamshergorawara@lupinpharma.com

or

Rajiv Pillai

Head – Investor Relations

Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin Limited

Ph: +91 98 20 552 083

Email: rajivpillai@lupinpharma.com

Safe Harbor Statement

Ortho-Novum® is a registered trademark of Janssen Pharmaceutical Inc.